- Home
- LSTA vs NRSN Comparison
LSTA vs NRSN Comparison
Compare LSTA & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LSTA
- NRSN
- Stock Information
- Founded
- LSTA 1980
- NRSN 2017
- Country
- LSTA United States
- NRSN Israel
- Employees
- LSTA N/A
- NRSN N/A
- Industry
- LSTA Misc Health and Biotechnology Services
- NRSN Biotechnology: Pharmaceutical Preparations
- Sector
- LSTA Health Care
- NRSN Health Care
- Exchange
- LSTA Nasdaq
- NRSN Nasdaq
- Market Cap
- LSTA 20.9M
- NRSN 30.6M
- IPO Year
- LSTA N/A
- NRSN 2021
- Fundamental
- Price
- LSTA $2.24
- NRSN $1.21
- Analyst Decision
- LSTA Strong Buy
- NRSN Buy
- Analyst Count
- LSTA 2
- NRSN 2
- Target Price
- LSTA $23.50
- NRSN $14.00
- AVG Volume (30 Days)
- LSTA 22.2K
- NRSN 1.3M
- Earning Date
- LSTA 11-11-2025
- NRSN 09-17-2025
- Dividend Yield
- LSTA N/A
- NRSN N/A
- EPS Growth
- LSTA N/A
- NRSN N/A
- EPS
- LSTA N/A
- NRSN N/A
- Revenue
- LSTA $1,070,000.00
- NRSN N/A
- Revenue This Year
- LSTA N/A
- NRSN N/A
- Revenue Next Year
- LSTA N/A
- NRSN N/A
- P/E Ratio
- LSTA N/A
- NRSN N/A
- Revenue Growth
- LSTA N/A
- NRSN N/A
- 52 Week Low
- LSTA $1.87
- NRSN $0.80
- 52 Week High
- LSTA $4.20
- NRSN $2.60
- Technical
- Relative Strength Index (RSI)
- LSTA 44.76
- NRSN 47.86
- Support Level
- LSTA $2.14
- NRSN $1.14
- Resistance Level
- LSTA $2.43
- NRSN $1.28
- Average True Range (ATR)
- LSTA 0.17
- NRSN 0.14
- MACD
- LSTA 0.02
- NRSN 0.02
- Stochastic Oscillator
- LSTA 42.42
- NRSN 12.50
About LSTA Lisata Therapeutics Inc.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.